Merck
  • Home
  • Search Results
  • Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients With Invasive Breast Cancer.

Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients With Invasive Breast Cancer.

Clinical journal of oncology nursing (2015-07-26)
Josephine Divers, Joyce O'Shaughnessy
ABSTRACT

The mammalian target of rapamycin (mTOR) inhibitor everolimus is approved (in combination with exemestane) for the treatment of postmenopausal women with advanced hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer resistant to endocrine therapy. Stomatitis is among the most frequently reported dose-limiting adverse events associated with everolimus use, often requiring treatment interruption or dose reduction. This article aims to educate nurses on the identification and management of stomatitis associated with mTOR inhibitors in hormone receptor-positive advanced breast cancer and to assist nurses with additional management techniques to improve patient outcomes. An evaluation of the literature highlighting the incidence, identification, and management of stomatitis in cancer was performed with a particular focus on breast cancer. In addition, the experiences of the authors' cancer center on managing stomatitis are described. A growing body of clinical evidence shows the benefits of adding steroid-based mouth rinses to the treatment plan. Clinical experience provides additional insight into stomatitis preventive and management strategies for patients with breast cancer receiving treatment with everolimus.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Phenol, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.5-100.5% (GC)
Sigma-Aldrich
Phenol, puriss., meets analytical specification of Ph. Eur., BP, USP, ≥99.5% (GC), crystalline (detached)
Sigma-Aldrich
Phenol, ≥96.0% (calc. on dry substance, T)
Sigma-Aldrich
Ethyl 4-aminobenzoate, 98%
Sigma-Aldrich
Iodine, ≥99.99% trace metals basis
Sigma-Aldrich
Iodine, 99.999% trace metals basis
Sigma-Aldrich
Phenol, puriss. p.a., ACS reagent, reag. Ph. Eur., 99.0-100.5%
Sigma-Aldrich
Phenol, unstabilized, ReagentPlus®, ≥99%
Sigma-Aldrich
Phenol, contains hypophosphorous as stabilizer, loose crystals, ACS reagent, ≥99.0%
Sigma-Aldrich
Phenol, unstabilized, purified by redistillation, ≥99%
Sigma-Aldrich
Iodine, anhydrous, beads, −10 mesh, 99.999% trace metals basis
Sigma-Aldrich
Phenol, ≥99%
Sigma-Aldrich
Phenol, BioUltra, for molecular biology, TE-saturated, ~73% (T)
Sigma-Aldrich
Phenol, for molecular biology
Sigma-Aldrich
Phenol, BioXtra, ≥99.5% (GC)
Sigma-Aldrich
Phenol solution, Equilibrated with 10 mM Tris HCl, pH 8.0, 1 mM EDTA, BioReagent, for molecular biology
Sigma-Aldrich
Phenol solution, Saturated with 0.1 M citrate buffer, pH 4.3 ± 0.2, BioReagent, for molecular biology
Supelco
Phenol solution, certified reference material, 500 μg/mL in methanol
Supelco
Phenol solution, 5000 μg/mL in methanol, certified reference material
Sigma-Aldrich
Phenol, natural, 97%, FG
Sigma-Aldrich
Iodine, Vetec, reagent grade, 99%
Supelco
Iodine, ReagentPlus®, ≥99.8% (titration)
Sigma-Aldrich
Iodine, ReagentPlus®, 99.7% trace metals basis, beads, 1-3 mm
Sigma-Aldrich
Iodine, puriss., ≥99.5% (RT), particles (round)
Sigma-Aldrich
Iodine, flakes, ReagentPlus®, ≥99%
Sigma-Aldrich
Iodine, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.8-100.5%
Sigma-Aldrich
Iodine, ACS reagent, ≥99.8%, solid
Sigma-Aldrich
Hydrogen peroxide solution, 34.5-36.5%
Sigma-Aldrich
Pyrrole, ≥98%, FCC, FG
Sigma-Aldrich
Hydrogen peroxide solution, 30 % (w/w) in H2O, contains stabilizer